Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled

Summary:

Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

ASA Scores Major Victory on Labor Epidural Supervision

Friday, January 21, 2011

CMS recently issued revised Interpretative Guidelines (IGs) to the Hospital Conditions of Participation that contain major victories for ASA’s regulatory lobbying efforts.  These guidelines revise major sections of the December 2009 CMS Hospital Interpretative Guidelines and are effective immediately.

CMS has removed language specifically exempting labor epidurals from the physician supervision requirements.  Hospitals are now required to “establish policies and procedures, based on nationally recognized guidelines, that address whether specific clinical situations involved anesthesia versus analgesia,” as well as, “the minimum qualifications and supervision requirements for each category of practitioner who is permitted to provide analgesia services.”  

When the 2009 IGs were released, ASA developed a comprehensive regulatory lobbying strategy, involving comment letters, meetings and discussions with appropriate CMS officials, with the goal of making substantive changes to the IGs.  ASA’s focus in all of its efforts was consistently on patient safety and quality of care coupled with emphasis on anesthesia as a continuum with no clear boundaries.  The strategy worked.  

Click here for updates on other victories ASA achieved in the new IGs.

Click here to read the CMS issued Revised Interpretive Guidelines.

Click here to read a memo from CMS on the Revised Interpretive Guidelines.

Click here to read FAQs released by CMS on the Revised Interpretive Guidelines.

 

 

« Back to Washington Alerts